Biogen Idec profit rises as new multiple sclerosis drug shines
Jan 29 (Reuters) - Biogen Idec Inc on Wednesday said fourth-quarter profit soared 57 percent, helped by strong sales of its new multiple sclerosis drug, Tecfidera.
The U.S. biotechnology company's net profit rose to $457.3 million, or $1.92 per share, in the quarter ended Dec. 31, from $292.1 million, or $1.23 per share, a year earlier.
Excluding special items, Biogen earned $2.34 per share. Analysts on average expected $2.28 per share, according to Thomson Reuters I/B/E/S.
The high-profile multiple sclerosis drug had sales of $398 million for the period. Total sales rose 39 percent to $1.97 billion, beating the analysts' average estimate of $1.93 billion.
- Exclusive: Angry with Washington, 1 in 4 Americans open to secession
- Secret Service investigates after man jumps White House fence, reaches doors
- N.Korea says imprisoned American tried to become 'second Snowden'
- Scots spurn independence in historic vote, devolution battle begins |
- French jets strike in Iraq, expanding U.S.-led campaign against Islamic State |